Joining Forces: Bmi1 Inhibition and Cisplatin Curb Squamous Carcinogenesis

Jessie A Brown; Markus Schober

doi:10.1016/j.stem.2017.04.008

Joining Forces: Bmi1 Inhibition and Cisplatin Curb Squamous Carcinogenesis

Cell Stem Cell. 2017 May 4;20(5):575-577. doi: 10.1016/j.stem.2017.04.008.

Authors

Jessie A Brown¹, Markus Schober²

Affiliations

¹ The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA.
² The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA. Electronic address: [email protected].

PMID: 28475877
DOI: 10.1016/j.stem.2017.04.008

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions. Chen et al. (2017) show that mouse and human HNSCCs and their metastases depend on Bmi1-expressing cancer stem cells and AP1 signaling and that simultaneously inhibiting Bmi1 or AP1, combined with Cisplatin, reduces tumor growth effectively in preclinical models.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Agents / therapeutic use
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / metabolism*
Cisplatin / therapeutic use*
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / metabolism*
Humans
Mice
Models, Biological
Polycomb Repressive Complex 1 / antagonists & inhibitors
Polycomb Repressive Complex 1 / metabolism*
Signal Transduction / drug effects
Squamous Cell Carcinoma of Head and Neck
Tamoxifen / therapeutic use

Substances

Antineoplastic Agents
Tamoxifen
Polycomb Repressive Complex 1
Cisplatin

Grants and funding

R01 CA181111/CA/NCI NIH HHS/United States